Cancer Prevention & Risk Factors Questions

The evidence-backed changes are: quit tobacco in every form (India's single largest preventable cancer cause), limit alcohol, keep a healthy weight, stay physically active, eat mostly plants, get HPV vaccination for children and young adults, get hepatitis B vaccination, and screen when eligible. Everything else — antioxidant supplements, superfoods, detox regimens — has little or no evidence behind it.

Yes — unambiguously. Tobacco, areca nut, and slaked lime in gutka and paan cause oral, throat, and esophageal cancer. India has one of the highest oral cancer rates in the world because of this. There's no 'safe' amount and no filter version. Quitting reduces risk gradually, and the earlier you stop, the more it falls.

Genetic testing (BRCA1/2, Lynch syndrome) is worthwhile if you have a strong family history — multiple close relatives with the same cancer, cancer at unusually young ages, or specific patterns like ovarian or male breast cancer. Without that pattern, routine testing rarely changes management. Talk to a genetic counsellor before testing so you understand what a positive or negative result actually means for you.

No. Evidence for specific superfoods or antioxidant pills preventing cancer is weak, and some high-dose antioxidant supplements (beta-carotene in smokers, vitamin E in men) have actually raised cancer risk in trials. A varied diet with plenty of fruits, vegetables, whole grains, and legumes is protective; concentrating on any single food or supplement isn't.

Yes. HPV vaccination given in adolescence (typically ages 9-14, effective up to 26) prevents the strains that cause most cervical cancer and a large share of throat, anal, and penile cancers. India's own Cervavac vaccine is now available at affordable prices. It works best before any sexual exposure to HPV, which is why vaccinating children is the priority.

Avoid smoking, limit alcohol, maintain a healthy weight, eat a balanced diet, stay physically active, and protect your skin from excessive sun exposure.

Common warning signs include unexplained weight loss, unusual lumps, persistent pain, unusual bleeding, changes in bowel or bladder habits, and a persistent cough. If these symptoms persist or are concerning, consult a doctor for proper evaluation and guidance.

There are three main approaches, and the choice depends heavily on where the suspicious tissue is and how fit the patient is. (1) CT-guided needle biopsy (transthoracic): a radiologist inserts a thin needle through the chest wall guided by real-time CT imaging. Most common for peripheral lung lesions. Takes 30–60 minutes under local anaesthetic, usually same-day discharge. Pneumothorax risk: 15–25% overall, higher in elderly with emphysema. (2) Bronchoscopic biopsy: a flexible scope passes through the airway under mild sedation to reach central or reachable lesions. Lower pneumothorax risk but misses many peripheral nodules. Safest for frail elderly patients with borderline lung function. (3) Video-assisted thoracoscopic surgery (VATS): minimally invasive surgical biopsy under general anaesthesia. Highest yield but highest risk for elderly patients with comorbidities (COPD, heart failure). Requires pulmonary function testing to confirm the patient can tolerate single-lung ventilation (FEV1 typically >1 litre needed). For an 80-year-old with moderate COPD, bronchoscopy or CT-guided biopsy under local anaesthesia is usually preferred over VATS.

Pneumothorax means air has leaked into the space between the lung and the chest wall, causing partial or full lung collapse. It's the most common complication of CT-guided needle biopsy, occurring in roughly 20% of cases overall — but in elderly patients with emphysema or COPD (whose lung tissue is already more fragile), the rate can be higher. Most post-biopsy pneumothoraces are small and resolve on their own within a few hours with close monitoring and supplemental oxygen. Warning signs to watch for at home after discharge: sudden sharp chest pain, rapidly worsening shortness of breath, feeling of tightness in the chest, rapid heart rate. These need immediate emergency care. A large or symptomatic pneumothorax requires chest tube drainage. Before any biopsy, ask your doctor: 'What will you do if I develop a pneumothorax during or immediately after the procedure, and what are the signs I should watch for at home?'

It's a genuinely difficult risk-benefit calculation, and no one answer fits all cases. The key questions the pulmonologist and thoracic surgeon will weigh: (1) How functionally significant is the heart failure? NYHA Class III-IV heart failure substantially increases procedural risk. Optimising diuretics and cardiac medications before biopsy may reduce risk. (2) How severe is the COPD? Spirometry (FEV1 and DLCO) will determine which biopsy type is safe. FEV1 below 40% predicted often rules out VATS. (3) How large and fast-growing is the lesion? A rapidly doubling nodule in a patient who could potentially benefit from treatment justifies higher procedural risk. A small, slow-growing nodule in an 80-year-old with Stage 3 COPD may reasonably be managed with close CT surveillance rather than biopsy. In India, AIIMS Delhi, Tata Memorial Mumbai, and Cancer Institute Chennai have thoracic multidisciplinary tumour boards that specifically review high-risk elderly biopsy cases. Getting a second opinion from such a team before agreeing to biopsy is entirely appropriate.

Yes — increasingly so, though they don't replace biopsy in every case. The main alternatives: (1) Liquid biopsy (blood-based ctDNA testing): a blood draw tests for circulating tumour DNA fragments. Now available at major cancer centres in India (₹15,000–35,000). Can identify actionable mutations (EGFR, ALK, ROS1) without a tissue procedure — useful when a patient is too frail for biopsy but might benefit from targeted therapy. Limitation: sensitivity is around 60–70% for early-stage disease, so a negative result doesn't rule out cancer. (2) PET-CT scan: identifies metabolically active tissue (cancer burns glucose faster than normal cells). Can help determine if a nodule is benign (low metabolic activity) without biopsy. Cost ₹12,000–20,000 at CGHS-empanelled centres. (3) CT surveillance: for incidentally found lung nodules under 8mm, guidelines (Fleischner Society) recommend 3–6 monthly CT scans rather than immediate biopsy to track growth rate. A stable nodule over 2 years is almost certainly benign. The right choice depends on whether knowing the exact diagnosis would change treatment — in a frail elderly patient who cannot tolerate chemotherapy or surgery regardless, a biopsy may cause harm without benefit.

HPV is the necessary cause, but several co-factors accelerate progression once you're infected: smoking (doubles the risk — chemicals concentrate in cervical mucus), long-term use of combined oral contraceptives beyond 5 years, having 3 or more full-term pregnancies, weakened immunity (HIV, transplant medications), and co-infection with chlamydia or HSV-2. Genetic factors and family history play a smaller role. This is why HPV vaccination plus quitting smoking plus regular screening is the strongest triple defence.

Typically 10-20 years for persistent high-risk HPV infection to progress through CIN 1 → CIN 2 → CIN 3 → invasive cancer. Most infections (roughly 90%) clear naturally within 1-2 years and never progress. This slow timeline is what makes screening (Pap smear every 3 years, HPV DNA test every 5 years) so effective — precancerous changes are catchable and treatable long before cancer develops.

Two main options: Serum Institute's Cervavac (indigenous quadrivalent, launched 2023) at ₹200-400 per dose, or MSD's Gardasil-9 (imported nonavalent, broader strain coverage) at ₹6,000-10,000 per dose. Some state governments now offer Cervavac free to schoolgirls under public immunization programmes — Sikkim was first (2023), followed by pilot rollouts in Karnataka and Punjab. Ask at your local government primary health centre or paediatric clinic.

Girls aged 9-14 need only 2 doses given 6 months apart (WHO simplified this in 2022 based on strong immunogenicity data). Girls and women aged 15-45 need 3 doses at 0, 1-2, and 6 months. Boys follow the same schedule. Missing a dose isn't a disaster — you can resume without restarting the series, but don't leave gaps longer than 12-15 months. Keep the paper record from your clinic; there's no national HPV vaccination portal (unlike CoWIN for COVID).

It is recommended for girls and boys aged 9–14 years. However, individuals up to age 45 can also receive it after consulting with a healthcare provider.

Yes, under India’s public immunization programs, the vaccine is available at minimal or no cost in government facilities.

No, but it protects against the most high-risk types (16 and 18), responsible for the majority of cervical cancers. Gardasil-9 offers broader protection.

Yes, it is recommended for men and boys to prevent genital warts and reduce transmission.

Long-term studies have shown the HPV vaccine to be extremely safe with no major health risks.

Best between ages 9 and 14, before any exposure to HPV — this is when the immune response is strongest and only 2 doses are needed (6 months apart). Girls aged 15 and older need the 3-dose schedule (at 0, 1-2, and 6 months). The vaccine works best before HPV exposure, which is why WHO and Indian pediatric guidelines target the 9-14 window.

The Serum Institute's Cervavac (indigenous quadrivalent HPV vaccine, launched 2023) costs ₹200-400 per dose — dramatically cheaper than imported options like Gardasil (₹2,000-4,000 per dose). Several state governments have started including HPV vaccination in their public immunization programmes for schoolgirls at no cost. Ask at a government primary health centre or paediatric clinic near you.

Yes — over 15 years of global safety data covering more than 500 million doses. Most side effects are mild: a sore arm at the injection site (most common), low-grade fever, or headache lasting 1-2 days. Serious side effects are extremely rare. WHO, ICMR, and the Indian Academy of Pediatrics all endorse the vaccine as safe and highly effective for preventing cervical cancer.

Yes — the HPV vaccine is approved for women up to age 45 in India. It's most effective before HPV exposure, but adult women who haven't been vaccinated can still benefit because the vaccine protects against high-risk HPV strains they may not yet have encountered. Talk to your gynecologist about whether it makes sense alongside regular Pap smear or HPV DNA screening after age 30.

High-risk HPV strains (mainly HPV 16 and 18, responsible for about 70% of cervical cancers globally) integrate their DNA into cervical cells. Two viral proteins — E6 and E7 — inactivate the cell's tumour suppressors (p53 and Rb), letting damaged cells keep dividing instead of self-destructing. Over 10-20 years of persistent infection, this leads to precancerous lesions and eventually invasive cancer. Most HPV infections clear on their own; only persistent ones progress.

No — CIN (cervical intraepithelial neoplasia) is a precancerous change, not cancer. It's graded CIN 1, 2, or 3 based on how deep the abnormal cells go: CIN 1 often clears on its own within 1-2 years; CIN 2/3 usually needs treatment (LEEP procedure, cryotherapy, or cone biopsy) to prevent progression to invasive cancer. CIN gives you 10-20 years of warning to act before cancer develops — this is exactly why regular screening works so well.

Common short-term: vaginal discharge or spotting, fatigue, mild cramping, and discomfort during applicator placement (usually managed with sedation or anaesthesia). Longer-term: vaginal narrowing or dryness, occasional bladder or bowel irritation. Most side effects are manageable, and using a vaginal dilator during recovery helps prevent narrowing. Discuss any severe or persistent symptoms with your oncologist.

Rarely — most upper back pain is muscle strain or posture-related, not cancer. Cancer causes a small fraction of back pain cases, and it usually comes with additional red flags: pain that doesn't improve with rest, worsens at night, unexplained weight loss, or unusual fatigue. If your pain is straightforward mechanical pain that eases with movement or rest, cancer is very unlikely.

Two reasons — shared genes and shared environment. Some inherited gene mutations (BRCA1, BRCA2, Lynch syndrome) raise risk for specific cancers across generations. Beyond genes, families often share the same diet, smoking exposure, air pollution, and infection risk — which explains clustering without any contagion. Genetic testing and family history discussion with your doctor helps you know your own risk.

Lung cancer is the most common, followed by metastatic cancer that has spread to the spine. Lung tumours can press on nerves or the spinal cord and refer pain to the upper back or between the shoulder blades. Cancers that commonly spread to bone — breast, prostate, kidney, thyroid — can also cause upper back pain when they reach the spine. Multiple myeloma is another cause worth mentioning to your doctor if pain is persistent.

See a doctor promptly if your back pain has any of these: doesn't improve after a few weeks of normal care, wakes you at night or is worse at night, comes with unexplained weight loss, fever, or numbness/weakness in arms or legs, or if you have a history of cancer. Sudden severe pain after a fall, or pain with bladder or bowel changes, is an emergency — go to a hospital, don't wait.

HPV (linked to cervical, throat, and anal cancers), hepatitis B and C viruses (liver cancer), H. pylori bacteria (stomach cancer), and Epstein-Barr virus (some lymphomas). HIV weakens the immune system and raises risk for multiple cancers. Vaccination against HPV and hepatitis B, along with treatment for H. pylori, meaningfully reduces later cancer risk.

No — cancer itself is not contagious. You cannot catch cancer through touch, kissing, sharing food, sex, or breathing the same air as someone with cancer. What can spread are viruses like HPV and hepatitis B/C, and bacteria like H. pylori — and those infections raise cancer risk over years. But the cancer isn't jumping between people; the underlying infection is.

For cervical cancer, brachytherapy plus external beam radiation is the gold standard — better than external beam alone. Brachytherapy delivers a concentrated radiation dose right at the tumour while sparing the bladder and rectum nearby. Studies consistently show higher tumour control and better survival with the combination. Most Indian oncology centres offer both.

Usually 3-5 sessions over 1-2 weeks, done as an outpatient. Each session takes a few hours — the applicator is placed, radiation delivered for 10-30 minutes, then the applicator removed. Overall brachytherapy is added at the end of a 5-6 week external beam radiation course, so total treatment runs about 6-8 weeks.

One feature is diagnostic when present: reduced or absent sensation in the patch. A leprosy skin lesion is typically hypopigmented (lighter than surrounding skin) or slightly reddish, has well-defined edges, and, critically, does not feel normal to touch, pinprick, or temperature. Ringworm and eczema itch and burn; leprosy lesions are usually numb or feel dull. To check at home: lightly touch the patch and adjacent normal skin with a wisp of cotton, then repeat with something warm and something cool. If the patch does not sense any of these normally, seek medical evaluation. Other clues: a thickened nerve near the patch that you can feel as a firm cord under the skin (common in the ulnar nerve near the elbow, the great auricular nerve in the neck, or the common peroneal nerve near the knee) is another leprosy-specific finding. Ringworm and eczema do not thicken nerves.

Casual social contact, sharing a workspace, brief conversations, handshakes, carries very low transmission risk because leprosy requires prolonged close exposure to spread. Household contacts and prolonged close contacts of untreated multibacillary cases have meaningfully elevated risk (roughly 5-10 times general population), which is why NLEP actively traces household contacts. Two protective factors: BCG vaccination in childhood offers partial protection; and once a patient starts multidrug therapy, they become non-infectious within days as the bacteria are killed by rifampicin. If you are a household contact of a diagnosed case, ask about single-dose rifampicin post-exposure prophylaxis (SDR-PEP). WHO now recommends this for close contacts and it reduces subsequent leprosy risk by roughly 50-60%. Do not wait for symptoms; contact tracing is the standard of care.

Latent TB means the M. tuberculosis bacteria are in your body but contained by your immune system inside granulomas, you have no symptoms, are not infectious, and cannot spread the disease. Chest X-ray is usually normal; TB is detected only through Mantoux test or IGRA blood test. Active TB means the bacteria have broken out of containment and are multiplying, causing symptoms (persistent cough, weight loss, night sweats, low-grade fever) and making you infectious to others. Roughly 5-10% of people with latent TB will develop active TB at some point in their lifetime, with the risk highest in the first 2 years after exposure and in anyone whose immune system weakens (HIV, diabetes, steroids, TNF inhibitors, aging). Whether latent TB needs treatment depends on individual risk. WHO recommends preventive treatment for household contacts of active TB cases, HIV-positive people, people starting immunosuppressive drugs, and healthcare workers with recent conversion. India's NTEP is expanding preventive TB treatment access, particularly for household contacts.

MDR-TB is TB resistant to at least isoniazid and rifampicin, the two most powerful first-line drugs. This resistance usually develops when patients receive inadequate treatment (wrong drugs, wrong doses, insufficient duration, or interruption), surviving bacteria multiply and become resistant. XDR-TB (extensively drug-resistant TB) is even more resistant, adding resistance to fluoroquinolones and injectable second-line drugs. India has among the largest number of MDR-TB cases globally. Treatment takes 9-24 months (vs 6 months for drug-sensitive TB), involves 4-7 medications simultaneously, causes more side effects, costs significantly more, and has lower cure rates (roughly 60-75% vs 85-95% for drug-sensitive TB). India's NTEP provides free MDR-TB diagnosis (GeneXpert MTB/RIF plus line probe assays) and treatment through dedicated DR-TB centres. Key patient rule: never stop TB treatment early even when feeling better, never skip doses, never take TB medications from unknown sources, creating MDR-TB harms both the patient and the community for decades.

Getting infected and getting sick are two different things. Roughly one-third of the global population carries M. tuberculosis in latent form after some exposure, but only 5-10% ever develop active disease. Whether you progress from infection to active disease depends on multiple factors: immune status (HIV infection multiplies risk 20-30 times, diabetes doubles risk, aging weakens immunity), nutritional status (malnutrition dramatically increases risk), co-existing lung damage (smoking, silicosis, previous TB), genetic factors (specific HLA variants affect susceptibility), medications suppressing immunity (steroids, chemotherapy, TNF inhibitors), and the initial infecting dose. In India, the confluence of high HIV in some regions, high diabetes prevalence (over 100 million adults), household crowding, and undernutrition explains why India carries such a disproportionate share of the global TB burden despite decades of control efforts.

BCG (Bacillus Calmette-Guérin) vaccine has real but limited effectiveness. It reliably prevents severe childhood forms of TB. TB meningitis and disseminated (miliary) TB, with efficacy of 60-80%. It is far less effective at preventing adult pulmonary TB, with published efficacy ranging from 0% to 80% depending on the population studied, the variability itself is a major research puzzle, possibly related to prior exposure to environmental mycobacteria in different geographies. Despite this variability, India continues universal BCG vaccination at birth because the severe childhood TB prevention justifies it in a high-burden country; deaths from meningitis or miliary TB in unvaccinated Indian infants would be substantial. Improved TB vaccines are in active development globally (M72/AS01E is in phase 3 trials), but until one is approved, BCG remains standard for Indian newborns and provides genuine protection for the childhood forms that matter most in the neonatal period.

Yes, directly. The WHO's paucibacillary (PB) vs multibacillary (MB) split decides the multidrug therapy (MDT) regimen and duration. Paucibacillary, five or fewer skin lesions, no bacilli seen on skin smear, is treated with rifampicin and dapsone for 6 months. Multibacillary, more than five lesions or bacilli present on smear, is treated with rifampicin, dapsone, and clofazimine for 12 months. The Ridley-Jopling five-type classification (TT/BT/BB/BL/LL) adds prognostic detail: which type predicts how likely a patient is to develop reactions (immune complications during or after treatment), how much nerve damage to anticipate, and how contagious the case is. In India, NLEP centres use both systems. WHO for treatment decisions, Ridley-Jopling for clinical description and follow-up planning.

Yes on both counts. India has the largest annual case count in the world, over 100,000 new cases detected each year through NLEP surveillance, concentrated in Bihar, Chhattisgarh, Jharkhand, Odisha, and parts of Maharashtra. And yes, leprosy is completely curable with multidrug therapy, the bacteria are killed within days of starting rifampicin, and full treatment (6-12 months depending on type) prevents relapse. What is not always reversible is the nerve damage and disability that develops before diagnosis, which is why early detection matters more than treatment access. NLEP provides diagnosis and MDT free of charge at every district hospital and most primary health centres, there is no financial barrier to treatment. The barrier is often social: fear of stigma delays presentation.

Yes — the type of organism determines both the clinical picture and the antibiotic choice. Typical bacterial pneumonia (Streptococcus pneumoniae, Haemophilus influenzae): starts abruptly — sudden high fever (39–40°C), rigor (shaking chills), productive cough with rust-coloured or purulent sputum, pleuritic chest pain (sharp pain worsening with deep breath, from pleural involvement). CXR shows lobar or segmental consolidation. Responds well to amoxicillin or beta-lactam antibiotics. Atypical pneumonia (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella): more gradual onset over several days, lower fever, dry or minimally productive cough (often described as a 'walking pneumonia' because patients may remain ambulatory), prominent extrapulmonary features — headache, myalgia, sore throat. CXR often shows interstitial or bilateral patchy infiltrates without clear lobar consolidation. Crucially: Mycoplasma has no cell wall, so penicillins and cephalosporins don't work. Treatment requires a macrolide (azithromycin, clarithromycin) or doxycycline. The clinical significance in India: Mycoplasma is particularly common in young adults aged 5–35, spreads in schools and colleges, and is a common cause of 'antibiotic not working' cases where amoxicillin was correctly prescribed but for the wrong organism. Viral pneumonia (influenza, SARS-CoV-2, RSV) can mimic atypicals but has distinct epidemiological patterns and responds to antivirals rather than antibiotics.

The pneumococcal vaccine protects against Streptococcus pneumoniae specifically — which is responsible for roughly 30–50% of community-acquired bacterial pneumonia cases requiring hospitalisation. It does not protect against Mycoplasma, Legionella, Klebsiella, viral pneumonia, or aspiration pneumonia from oral bacteria. So it is valuable but partial. Two types of pneumococcal vaccine are available in India: PCV13 (Prevenar 13) — covers 13 serotypes including the most virulent ones; recommended for all children in the Universal Immunisation Programme (given at 6 weeks, 14 weeks, and 9 months in states where UIP covers it). Pneumovax 23 (PPSV23) — covers 23 serotypes; recommended for adults. Who should get PPSV23: adults ≥65; adults of any age with COPD, diabetes, heart failure, asthma requiring hospitalisation, liver disease, or sickle cell disease; those without a spleen (asplenia — very high pneumococcal pneumonia risk); immunocompromised patients including those on long-term steroids. In India, adult pneumococcal vaccination is underutilised — most people in high-risk groups above are unvaccinated. The vaccine reduces hospitalisation for pneumococcal pneumonia by approximately 45–50% in the elderly. Annual influenza vaccine is a separate, important protection — influenza damages airway epithelium, creating the perfect entry point for secondary bacterial pneumonia; the 'flu then pneumonia' sequence was the main cause of death in the 1918 pandemic and remains important today. Both vaccines are available at private hospitals and many government centres; PPSV23 costs approximately ₹1,500–2,500 at private pharmacies.

Yes, most adults benefit from at least the hepatitis B vaccine, and many should also get hepatitis A depending on their risk. Hepatitis B is a major cause of chronic liver disease, cirrhosis and liver cancer, and it spreads through blood, sexual contact, and shared needles — the WHO recommends universal vaccination for all adults who were not vaccinated in childhood. Hepatitis A spreads through contaminated food and water, so people travelling to areas with poor sanitation, those with chronic liver disease, healthcare workers, food handlers, and men who have sex with men are strongly advised to get it. Vaccination is safe, inexpensive, and gives long-lasting protection — usually decades — from two life-changing infections.

Hepatitis A needs 2 doses six months apart; hepatitis B needs 3 doses on a 0, 1, and 6-month schedule. For hepatitis A, the first shot gives short-term protection within 2–4 weeks; the second shot 6 months later locks in long-term immunity — usually 20+ years. For hepatitis B, the standard schedule is dose 1 at the start, dose 2 one month later, and dose 3 five months after that — the third dose is essential for durable immunity. A newer 2-dose adult hepatitis B vaccine (Heplisav-B) uses shots one month apart and is now available in some countries. A combination hepatitis A + B vaccine also exists and follows a 3-dose schedule (0, 1, 6 months). Missing a dose usually means completing the series later, not restarting.

Most side effects are mild and short-lived — sore arm, tiredness or low-grade fever for a day or two. The most common reactions are soreness, redness or swelling at the injection site, plus mild headache, fatigue, or a slight fever. These usually settle within 24 to 48 hours. Serious side effects are extremely rare. Severe allergic reactions (anaphylaxis) occur in fewer than 1 per million doses. People with a known severe allergy to any vaccine ingredient (like yeast, in the case of the hepatitis B vaccine) should tell their doctor before getting the shot. The vaccine cannot cause hepatitis infection because it contains only viral proteins, not live virus.

Most healthy adults do not need boosters or antibody testing once the full vaccine series is complete. Immunity from both hepatitis A and hepatitis B vaccines usually lasts 20 years or more, and the immune system has memory cells that can respond quickly even if antibody levels drop over time. However, certain high-risk groups — healthcare workers exposed to blood, dialysis patients, people living with HIV or on immunosuppressive drugs, and infants of hepatitis B-positive mothers — should get antibody testing (anti-HBs level) 1–2 months after the final dose, and boosters may be given if the level is below the protective threshold (10 mIU/mL). If you're unsure about your childhood vaccine history, an antibody test can confirm whether you're still protected.

Get to a hospital or clinic immediately — post-exposure treatment works best within 24 hours and must start within 7 days. If you've had a needlestick injury, unprotected sex with a known hepatitis B-positive partner, or any other significant exposure to blood or body fluids, wash the site with soap and water (do not squeeze or scrub), then go straight to an emergency department or occupational health service. The doctor will assess the exposure, test both you and (if possible) the source person, and decide what post-exposure prophylaxis (PEP) is needed based on your vaccination status. Delay reduces the chance PEP works — every hour matters, especially in the first 24. Don't wait for symptoms; hepatitis B often has no early signs but can still cause serious long-term liver damage.